vs-105
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 24, 2017 (NCT03043482)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Vitamin D receptorMODULATOR
VDR modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 5-(2-(1-(1-(3-hydroxy-2,3-dimethylbutoxy)ethyl)-7alpha-methyldihydro-1h-inden-4(2h,5h,6h,7h,7alphah)-ylidene)ethylidene)-2-methylenecyclohexane-1,3-diol
- vs-105
- vs-105
- vs-105
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03043482 | Phase 1 | Jan 24, 2017 | Davita Clinical Research, Vidasym, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Davita Clinical Research | For profit | 1 | 0 | 1 | 2017 |
| Vidasym, Inc. | For profit | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1